




Accepted Abstracts for CROI 2016

Protocol	Title	Authors	Presentation Type
Tuesday, 23 February 2016			
P1084s	Impact of maternal tenofovir disoproxil fumarate on newborn bone mineral content	Siberry GK, Tierney C, Stranix-Chibanda L, Marr C, Shepherd JA, Browning R, Kalkwarf H, George K, and Fowler MG	Oral presentation, 10:00 am – 12:00 pm
Lab abstract	Breast Milk and In Utero HIV-1 Transmission Select for Unique Envelope Signatures	Wilkinson T, Nakamura K, Heath L, Sobrera E, Decker W, Semrau K, Sinkala M, Kankasa C, Webb N, Lee B, Thea D, Kuhn L, Mullins J, and Aldrovandi G	Oral presentation, 10:00 am – 12:00 pm
P1026s	Dolutegravir Pharmacokinetics in HIV-Infected Pregnant and Postpartum Women	Mulligan N, Best B, Capparelli E, Stek A, Barr E, Smith E, Chakhtoura N, Wang J, Burchett S, and Mirochnick M	Poster and themed discussion, 1:45 pm – 2:45 pm
P1026s	Rilpivirine Female Genital Tract Concentrations in Pregnant and Postpartum Women	Mirochnick M, Best B, Kashuba A, Sykes C, Schauer A, Wang J, Stek A, Smith E, Chakhtoura N, and Capparelli E	Poster and themed discussion, 1:45 pm – 2:45 pm
DACS 095	Nevirapine Dosing for Treatment in the First Months of Life	Mirochnick M, Capparelli E, Nielsen-Saines K, Pilotto J, Musoke P, Shetty A, and Luzuriaga K	Poster and themed discussion, 1:45 pm – 2:45 pm
P1026s	Pharmacokinetics of increased dose darunavir during late pregnancy and postpartum	Stek A, Best B, Caparrelli E, Wang J, Shapiro D, Cressey T, Smith E, Kreitchman R, Chakhtoura N, and Mirochnick M	Poster
P1026s	A comparison of the pharmacokinetics of efavirenz during pregnancy and postpartum	Schalkwijk S, Colbers A, Best B, Stek A, Hawkins D, Wang J, Mirochnick M, and Burger D	Poster
HPTN 040	Maternal CMV urinary shedding and congenital CMV infection in HIV-infected	Adachi K, Xu J, Ank B, Watts D, Joao E, Pilotto JH, Bryson Y, Veloso V, Mofenson L, and Nielsen-Saines K	Poster



Accepted Abstracts for CROI 2016

Protocol	Title	Authors	Presentation Type
Tuesday, 23 February 2016 (continued)			
P1073	Risk factors for BCG IRIS in HIV-infected infants starting antiretroviral therapy	George V, Nemes E, Toefy A, Hanekom W, Cotton M, Mitchell C, Oleski J, Zimmer B, Fenton T, Pahwa S, for the IMPAACT P1073	Poster
P1072	Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection	Uprety P, Lindsey J, Levin M, Rainwater-Lovett K, Ziemniak C, Kaplan S, Nelson M, Zadzilka A, Weinberg A, and Persaud D	Poster
Wednesday, 24 February 2016			
P1093	IMPAACT P1093: Dolutegravir in 6-12 year old HIV infected children: 48-week results	Wiznia A, Alvero C, Fenton T, George K, Townley E, Hazra R, Heckman B, Buchannan A, Vavro C, and Viani R	Poster and themed discussion, 1:45 pm – 2:45 pm
PHACS	HIV-1 DNA dynamics over a decade or more of viral suppression in perinatal infection	Uprety P, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Chen Y, Siminski S, Van Dyke R, Seage G, and Persaud D	Poster
Thursday, 25 February 2016			
Lab abstract	Infant CD4+ T cells have a distinct immunophenotype by single cell analysis	Lincez P, Li F, Lee D, Nakamura K, Tobin N, and Aldrovandi G	Poster
P1070	Optimal use of efavirenz in HIV+/ TB+ co-infected children aged 3 to 24 months	Bolton C, Samson P, Capparelli E, Bwakura-Dangarembizi M, Jean-Phillippe P, Chakhtoura N, Bennis A, Zimmer B, Jackson C, and Chadwick E	Poster
P1088	NextGen sequencing defines response to H1N1 vaccination in HIV-infected individuals	Yin L, Rodriguez C, Yao J, Chang K, Karki M, Sleasman J, and Goodenow M	Poster